Evidence map›Paper›PMID 20161783›Full record

ArticlePloS one2010

Posttranslational modifications, localization, and protein interactions of optineurin, the product of a glaucoma gene.

Hongyu Ying, Xiang Shen, BumChan Park, Beatrice Y J T Yue

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Protein misfolding and mitochondrial dysfunction in glaucoma.Frontiers in cell and developmental biology · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Mechanisms of Selective Autophagy.Journal of molecular biology · 2016
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Hongyu YingDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States of America.
Xiang Shen
BumChan Park
Beatrice Y J T Yue
University of Illinois Chicago · US

Funding

Translational Core for Therapeutic and Diagnostic DevelopmentP30EY001792 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MCANANY, JAMES JASON · 1985 to 2025
$14.8M
BIOLOGY OF TRABECULAR MESHWORK IN HEALTH &DISEASER01EY005628 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 1985 to 2009
$3.4M
CONNECTIVE TISSUE AND RNA STUDIES OF DISEASED CORNEASR01EY003890 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 1985 to 2007
$3.0M
Cellular Processing of Optineurin, the Product of a Glaucoma GeneR01EY018828 · NEI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI YUE, BEATRICE Y.J.T. · 2009 to 2012
$1.7M
NEI NIH HHS EY003890NEI NIH HHS EY005628NEI NIH HHS EY01792NEI NIH HHS EY018828NEI NIH HHS P30 EY001792NEI NIH HHS R01 EY003890NEI NIH HHS R01 EY005628NEI NIH HHS R01 EY018828
6 · The paper itself

Abstract

backgroundGlaucoma is a major blinding disease. The most common form of this disease, primary open angle glaucoma (POAG), is genetically heterogeneous. One of the candidate genes, optineurin, is linked principally to normal tension glaucoma, a subtype of POAG. The present study was undertaken to illustrate the basic characteristics of optineurin. METHODOLOGY/PRINCIPAL

findingsLysates from rat retinal ganglion RGC5 cells were subjected to N- or O-deglycosylation or membrane protein extraction. The phosphorylation status was evaluated after immunoprecipitation. It was found that while phosphorylated, optineurin was neither N- nor O-glycosylated, and was by itself not a membrane protein. RGC5 and human retinal pigment epithelial cells were double stained with anti-optineurin and anti-GM130. The endogenous optineurin exhibited a diffuse, cytoplasmic distribution, but a population of the protein was associated with the Golgi apparatus. Turnover experiments showed that the endogenous optineurin was relatively short-lived, with a half-life of approximately 8 hours. Native blue gel electrophoresis revealed that the endogenous optineurin formed homohexamers. Optineurin also interacted with molecules including Rab8, myosin VI, and transferrin receptor to assemble into supermolecular complexes. When overexpressed, optineurin-green fluorescence protein (GFP) fusion protein formed punctate structures termed "foci" in the perinuclear region. Treatment of nocadazole resulted in dispersion of the optineurin foci. In addition, tetracycline-regulated optineurin-GFPs expressing RGC5 stable cell lines were established for the first time. CONCLUSIONS/SIGNIFICANCE: The present study provides new information regarding basic characteristics of optineurin that are important for future efforts in defining precisely how optineurin functions normally and how mutations may result in pathology. The inducible optineurin-GFP-expressing cell lines are also anticipated to facilitate in-depth studies of optineurin. Furthermore, the demonstrations that optineurin is an aggregation-prone protein and that the foci formation is microtubule-dependent bear similarities to features documented in neurodegenerative diseases, supporting a neurodegenerative paradigm for glaucoma.

Indexed as

Protein Processing, Post-TranslationalAnimalsBlotting, WesternCell Cycle ProteinsCell LineGlycosylationGolgi ApparatusGreen Fluorescent ProteinsHumansLow Tension GlaucomaMembrane Transport ProteinsMicroscopy, ConfocalMyosin Heavy ChainsPhosphorylationProtein BindingProtein MultimerizationCell Cycle ProteinsGreen Fluorescent ProteinsMembrane Transport ProteinsMyosin Heavy Chainsmyosin VIOPTN protein, humanReceptors, TransferrinRecombinant Fusion ProteinsTranscription Factor TFIIIA

Identifiers

PMID20161783
PMCPMC2820081
OpenAlexW2029303246

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.